Share Buyback / Capital Return

Zydus Lifesciences Announces ₹1,100 Crore Share Buyback at ₹1,150 Per Share

NSE

zyduslife

BSE

532321

Zydus Lifesciences Limited has approved a share buyback worth up to ₹1,100 crore through the tender offer route. The company plans to buy back up to 95.65 lakh equity shares at ₹1,150 per share, representing 0.95% of the total paid-up equity share capital.

PRICE-SENSITIVE TRIGGER

Event: Board approval for share buyback

Type: Share Buyback / Capital Return

Impact: Positive

Immediate Effect: The buyback signals management confidence in the company’s financial strength and is expected to support shareholder value through capital return and potential earnings-per-share improvement.

Key Metrics:

Buyback Size: ₹1,100 crore
Buyback Price: ₹1,150 per share
Maximum Shares to be Bought Back: 95,65,217 equity shares
Buyback Percentage: 0.95% of paid-up equity capital
Record Date: May 29, 2026

Highlight Metric:

Zydus Lifesciences approved a ₹1,100 crore buyback at ₹1,150 per share through the tender offer route.

What Happened ?

The Board of Zydus Lifesciences Limited approved a proposal to buy back up to 95.65 lakh equity shares at a price of ₹1,150 per share via the tender offer mechanism.

The total buyback consideration will not exceed ₹1,100 crore, excluding transaction-related expenses and taxes. The buyback will be conducted on a proportionate basis from eligible shareholders, including promoters and promoter group entities, as on the record date.

The company also constituted a Buyback Committee to oversee implementation of the buyback process and fixed May 29, 2026 as the record date for determining shareholder eligibility.

Key Details

Buyback Structure:

Buyback approved through the tender offer route.
Maximum buyback size capped at ₹1,100 crore.
Buyback price fixed at ₹1,150 per equity share.
Up to 95,65,217 shares proposed to be repurchased.

Shareholder Eligibility:

Record date fixed as May 29, 2026.
All eligible shareholders, including promoters, can participate.
Buyback will be executed proportionately under SEBI Buyback Regulations.

Shareholding Snapshot:

Promoter and promoter group currently hold approximately 74.99% stake.
Foreign portfolio investors hold around 6.86%.
Mutual funds hold approximately 4.90%.

Regulatory & Execution Process:

Buyback Committee formed to manage execution and compliance matters.
Public announcement and letter of offer will be released subsequently.
Company retains flexibility to revise buyback price before record date as permitted under regulations.

Note:

The buyback size represents approximately 5.16% of standalone net worth and 3.84% of consolidated net worth as per FY26 audited financial statements.

Risk Analysis

Key Risks:

Limited impact on valuation if broader market sentiment weakens.
Reduced cash reserves after buyback execution.
Shareholder acceptance ratio may vary depending on participation levels.
Regulatory timelines and procedural compliance could affect execution schedule.

Worst Case Scenario:

If the market price remains significantly above or near the buyback price, shareholder participation may remain lower than expected, reducing overall buyback effectiveness.

Risk Level: Low

Company Commentary

The Board approved the buyback of up to 95.65 lakh shares at ₹1,150 per share.
The company stated that the buyback will be undertaken through the tender offer route in accordance with SEBI regulations.
Zydus Lifesciences fixed May 29, 2026 as the record date for shareholder eligibility.
A Buyback Committee has been constituted for operational execution and compliance oversight.

Official Exchange Filing: Zydus Lifesciences Limited